| Company Name: | Inovio Biomedical Corporation | | Ticker Symbol: | INO | | | WWW Address: | www.inovio.com | | CEO: | Dr. J. Joseph Kim, Ph.D. | | No. of Employees: | 27 | | Common Issue Type: | CS | | Business Description: | A biomedical company, focused on the development of next-generation vaccines to prevent or treat cancers and chronic infectious diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 1.42 |  -0.08 | 1.42 | 1.44 | 1.55 | 1.68 | 1.50 | 648034 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 160.3 | 102.1 | 2.66 | -0.30 | 0.00 | 0.0 | 0.0 | 3.40 - 0.17 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 1.57 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 160.3 | mil |
| Latest Shares Outstanding | 102.1 | mil |
| Earnings pS (EPS) | -0.30 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 77,704 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 61.4 | mil |
| Float as % of Shares Outstanding | 71.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 200.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 98.90 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -22.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -30.6 | % |
| Current Ratio | 2.3 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.18 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.27 | $ |
| Cash pS | 0.32 | $ |
| Book-Value pS | 0.66 | $ |
| Tangible Book-Value pS | 0.43 | $ |
| Cash Flow pS | -0.19 | $ |
| Free Cash Flow pS | -0.13 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.37 | |
| Price/Tangible Book Ratio | 3.65 | |
| Price/Cash Flow | -8.3 | |
| Price/Free Cash Flow | -12.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.6 | 101 | 15,028 | 26,045 |
| 4 Weeks | 1.68 | 1.03 | 1.04 | 51.0 | 141 | 11,443 | 183,095 |
| 13 Weeks | 2.43 | 1.02 | 2.11 | -25.6 | 69 | 14,206 | 852,374 |
| 26 Weeks | 3.40 | 0.60 | 0.60 | 161.7 | 217 | 25,594 | 3,173,622 |
| 52 Weeks | 3.40 | 0.17 | 0.19 | 748.6 | 688 | 13,053 | 3,237,025 |
| YTD | 3.40 | 0.18 | - | 201.9 | 247 | 14,263 | 3,223,404 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 1.34 | 1.27 | 1.38 | 1.27 | 1.01 | 2.66 | 2.87 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 23.90 | 31.7 | 10.21 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 59.23 | NA | -40.91 |
| R&D | 1.45 | NA | -12.91 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 267.5 | 701.9 | -56.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.05 | 0.02 | -0.03 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 1.42 |
| Current Ratio | 1.0 |
| Quick Ratio (Acid Test) | 1.0 |
| Liquidity Ratio (Cash) | 0.96 |
| Receivables Turnover | 2.3 |
| Average Collection Period | 157 |
| Working Capital/Equity | 2.9 |
| Working Capital pS | 0.01 |
| Cash-Flow pS | -0.27 |
| Free Cash-Flow pS | -0.27 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.39 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 51.0 |
| Total Debt/Equity (Gearing Ratio) | 0.63 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 27.1 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.18 |
| Tobin's Q Ratio | 4.11 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -13.05 |
| Enterprise Value (EV)/Free Cash Flow | -12.67 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 3.65 |
| Price/Book Ratio - LTM | 2.37 |
| Price/Cash Flow Ratio | -8.3 |
| Price/Free Cash Flow Ratio - LTM | -12.5 |
| Price/Sales Ratio | 23.46 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.33 |
| Tangible Book Value pS - LTM | 0.43 |
| Book Value pS - LTM | 0.66 |
| Capital Invested pS | 0.19 |
| Cash pS - LTM | 0.32 |
| Cash Flow pS - LTM | -0.19 |
| Free Cash Flow pS - LTM | -0.13 |
| Earnings pS (EPS) | -0.30 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -558.20 |
| Free Cash Flow Margin 5YEAR AVG | -391.59 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.11 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.11 |
| Return on Capital Invested (ROCI) | -67.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -56.8 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -33.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | -38.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 115 |
| Revenue per Employee | 77,704 |
| Net Income per Employee | -480,222 |
| Average Collection Period | 115 |
| Receivables Turnover | 2.3 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 17.97 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 3.78 |
| Fixed Assets Turnover | 0.09 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.15 |
| Revenue per $ Plant | 5.93 |
| Revenue per $ Common Equity | 0.11 |
| Revenue per $ Capital Invested | 0.11 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 476.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 242.7 |
| Research & Devlopment (R&D) as % of Revenue | 274.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 274.1 |
|
|  
|
| |
 |  |